Evidence map›Paper›PMID 41723159›Full record

ArticleCell death & disease2026

DNMT2 inhibits anaplastic thyroid cancer progression by downregulating 5'tiRNA

Ruixin Zhou, Baizhao Li, Mingyu Cao, Zhijing Wu, Fada Xia, Xinying Li

Abstract read
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ruixin ZhouDepartment of General Surgery, Xiangya Hospital of Central South University, Changsha, Hunan, China.ORCID http://orcid.org/0000-0001-7985-5260
Baizhao LiDepartment of General Surgery, Xiangya Hospital of Central South University, Changsha, Hunan, China.ORCID http://orcid.org/0009-0007-7049-5511
Mingyu CaoDepartment of General Surgery, Xiangya Hospital of Central South University, Changsha, Hunan, China.
Zhijing WuDepartment of General Surgery, Xiangya Hospital of Central South University, Changsha, Hunan, China.ORCID http://orcid.org/0009-0004-9435-8843
Fada Xia *Department of General Surgery, Xiangya Hospital of Central South University, Changsha, Hunan, China. xiafada@xiangya.com.cn.ORCID http://orcid.org/0000-0002-8904-897X
Xinying Li *Department of General Surgery, Xiangya Hospital of Central South University, Changsha, Hunan, China. 403805@csu.edu.cn.ORCID http://orcid.org/0009-0008-9786-2497

Funding

National Natural Science Foundation of China (National Science Foundation of China) No. 82270835National Natural Science Foundation of China (National Science Foundation of China) No.82403230
6 · The paper itself

Abstract

Complex tRNA methylation modifications collectively maintain the structural integrity and functional efficiency of tRNA. DNA methyltransferase 2 (DNMT2) regulates the m5C methylation status of tRNA, thereby reprogramming its structure and influencing cancer progression. However, the precise mechanisms through which DNMT2 affects tumor development via tRNA methylation remain insufficiently understood. In this study, we demonstrate that reduced DNMT2 expression promotes the progression of anaplastic thyroid carcinoma (ATC). Specifically, in ATC, DNMT2 catalyzes m5C38 methylation on three tRNAs: tRNA-Asp-GUC, tRNA-Gly-GCC, and tRNA-Val-AAC. Loss of DNMT2 leads to an increased abundance of 5'tiRNA

Indexed as

DNA (Cytosine-5-)-MethyltransferasesRNA, TransferThyroid Carcinoma, AnaplasticAnimalsCell Line, TumorDisease ProgressionDown-RegulationDoxorubicinGene Expression Regulation, NeoplasticHumansMiceMice, NudeRNA MethylationThyroid NeoplasmsDNA (Cytosine-5-)-MethyltransferasesDoxorubicinRNA, Transfer

Identifiers

PMID41723159
PMCPMC12949022

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.